Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Keith R Abrams

Showing results (31-40 of 151) with videos related to

Pageof 16
Sort By:
Health Economics|September 19, 2006
Predicting costs over time using Bayesian Markov chain Monte Carlo methods: an application to early inflammatory polyarthritisNicola J Cooper, Paul C Lambert, Keith R Abrams, et al.
International Journal of Epidemiology|August 24, 2005
The choice of a genetic model in the meta-analysis of molecular association studiesCosetta Minelli, John R Thompson, Keith R Abrams, et al.
Journal of Market Access & Health Policy|April 24, 2026
Mapping the Use of Real-World Evidence Across the EU Health Technology Assessment Regulation: Methodological Considerations, Challenges, and Opportunities for HarmonizationGrammati Sarri, Bengt Liljas, Keith R Abrams, et al.
Health Economics|February 26, 2004
Comprehensive decision analytical modelling in economic evaluation: a Bayesian approachNicola J Cooper, Alex J Sutton, Keith R Abrams, et al.
Cancer Medicine|May 13, 2016
Adjusting for treatment switching in the METRIC study shows further improved overall survival with trametinib compared with chemotherapyNicholas R Latimer, Helen Bell, Keith R Abrams, et al.
Neurourology and Urodynamics|January 13, 2016
Patient factors associated with onabotulinum toxin A treatment outcome in women with detrusor overactivityRhiannon K Owen, Keith R Abrams, Christopher Mayne, et al.
Neurourology and Urodynamics|August 27, 2016
Comparison of the effectiveness of repeated injections of onabotulinum toxin A for refractory idiopathic detrusor overactivity: analysis of an open label extension of a randomized trial (the RELAX study)Rhiannon K Owen, Keith R Abrams, Christopher Mayne, et al.
Stroke|April 1, 2006
Cerebral blood flow threshold of ischemic penumbra and infarct core in acute ischemic stroke: a systematic reviewElisabetta Bandera, Marco Botteri, Cosetta Minelli, et al.
The Oncologist|June 5, 2015
Adjusting for the Confounding Effects of Treatment Switching-The BREAK-3 Trial: Dabrafenib Versus DacarbazineNicholas R Latimer, Keith R Abrams, Mayur M Amonkar, et al.
Obstetrics and Gynecology|February 3, 2007
Urinary diaries: a comparison of data collected for three days versus seven daysDouglas G Tincello, Kate S Williams, Miland Joshi, et al.
Pageof 16

Showing results (31-40 of 151) with videos related to

Sort By:
Pageof 16
Health Economics|September 19, 2006
Predicting costs over time using Bayesian Markov chain Monte Carlo methods: an application to early inflammatory polyarthritisNicola J Cooper, Paul C Lambert, Keith R Abrams, et al.
International Journal of Epidemiology|August 24, 2005
The choice of a genetic model in the meta-analysis of molecular association studiesCosetta Minelli, John R Thompson, Keith R Abrams, et al.
Journal of Market Access & Health Policy|April 24, 2026
Mapping the Use of Real-World Evidence Across the EU Health Technology Assessment Regulation: Methodological Considerations, Challenges, and Opportunities for HarmonizationGrammati Sarri, Bengt Liljas, Keith R Abrams, et al.
Health Economics|February 26, 2004
Comprehensive decision analytical modelling in economic evaluation: a Bayesian approachNicola J Cooper, Alex J Sutton, Keith R Abrams, et al.
Cancer Medicine|May 13, 2016
Adjusting for treatment switching in the METRIC study shows further improved overall survival with trametinib compared with chemotherapyNicholas R Latimer, Helen Bell, Keith R Abrams, et al.
Neurourology and Urodynamics|January 13, 2016
Patient factors associated with onabotulinum toxin A treatment outcome in women with detrusor overactivityRhiannon K Owen, Keith R Abrams, Christopher Mayne, et al.
Neurourology and Urodynamics|August 27, 2016
Comparison of the effectiveness of repeated injections of onabotulinum toxin A for refractory idiopathic detrusor overactivity: analysis of an open label extension of a randomized trial (the RELAX study)Rhiannon K Owen, Keith R Abrams, Christopher Mayne, et al.
Stroke|April 1, 2006
Cerebral blood flow threshold of ischemic penumbra and infarct core in acute ischemic stroke: a systematic reviewElisabetta Bandera, Marco Botteri, Cosetta Minelli, et al.
The Oncologist|June 5, 2015
Adjusting for the Confounding Effects of Treatment Switching-The BREAK-3 Trial: Dabrafenib Versus DacarbazineNicholas R Latimer, Keith R Abrams, Mayur M Amonkar, et al.
Obstetrics and Gynecology|February 3, 2007
Urinary diaries: a comparison of data collected for three days versus seven daysDouglas G Tincello, Kate S Williams, Miland Joshi, et al.
Pageof 16